Understanding the Role of FGF21 in Psoriasis Treatment

Psoriasis remains a challenging chronic immune-mediated skin condition. It involves excessive epidermal growth and persistent systemic inflammation. While existing therapies help many patients, clinicians still face hurdles regarding long-term safety and consistent efficacy. Recent research into FGF21 in psoriasis treatment suggests a novel metabolic approach to managing this dermatological disorder. Fibroblast growth factor 21 (FGF21) is typically recognized for its metabolic regulation. However, it also demonstrates potent anti-inflammatory properties that could support tissue homeostasis in psoriatic skin.

Mechanisms of Action: NF-κB and Autophagy

The study utilized an imiquimod-induced mouse model to simulate psoriasis-like symptoms. Researchers found that FGF21 administration significantly attenuated skin lesions and reduced systemic inflammatory cytokines. Specifically, the protein helps restore the balance between cell proliferation and apoptosis in keratinocytes. This effect occurs primarily through the suppression of the NF-κB signaling pathway. Furthermore, the FGF21 in psoriasis treatment mechanism involves the inhibition of PI3K/AKT and STAT3 activation, which are key drivers of epidermal hyperplasia.

Notably, the anti-inflammatory benefits of FGF21 appear to be autophagy-dependent. When researchers used chloroquine to inhibit autophagy, the protective benefits of FGF21 vanished. This suggests that FGF21 actively restores autophagy pathways to clear cellular stress and maintain epidermal health. Consequently, increasing SIRT1 expression while decreasing STAT3 activation provides a multifaceted defense against the runaway inflammation seen in psoriasis.

Future Clinical Implications for Dermatology

The preliminary tolerability of FGF21 in animal models is encouraging. In these studies, subjects maintained stable body weights and showed healthy histological profiles. Therefore, FGF21 represents a promising therapeutic candidate not only for psoriasis but potentially for other autoimmune inflammatory disorders. Clinicians should monitor further research as these metabolic regulators move toward human clinical trials.

Frequently Asked Questions

How does FGF21 help reduce skin inflammation?

FGF21 reduces inflammation by suppressing the NF-κB pathway and restoring the balance of autophagy. This process helps regulate keratinocyte growth and lowers the production of systemic pro-inflammatory cytokines.

Is FGF21 currently used in clinical practice for psoriasis?

Currently, FGF21 is being investigated in preclinical models and early-stage research. While it shows great promise for FGF21 in psoriasis treatment, it is not yet an approved standard of care for dermatological patients.

Why is autophagy important in psoriasis management?

Autophagy is the body's way of cleaning out damaged cells. In psoriasis, this process is often impaired. Restoring autophagy helps control excessive cell proliferation and reduces the inflammatory triggers that cause skin plaques.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Guan X et al. Fibroblast growth factor 21 ameliorates psoriasiform inflammation and epidermal hyperplasia through the regulation of NF-κB and autophagy pathways. Int Immunopharmacol. 2026 May 25. doi: undefined. PMID: 42184482.

Kim SY, et al. FGF21 as a novel metabolic regulator in systemic inflammation. Endocrine Reviews. 2023;44(2):145-162.

Zhang J, et al. Autophagy dysregulation in inflammatory skin diseases: A review of current evidence. Frontiers in Immunology. 2024;15:1342118.